Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration ...
Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid ...
Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...
16h
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan
BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...
Validated clinical efficacy and scalable manufacturing propel exosomes from research discovery to commercial therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback